Towards the Biomarker-Driven Development and their Global Impact in the Evidence-Based Clinical Practice of Personalized and Precision Healthcare Services

Authors

  • Sergey Suchkov “Semeinaya-Family” Clinical Practice Network, Russia, Dept for Clinical Allergology & Immunology of the Russian University of Medicine, Moscow, Russia, EPMA, Brussels, EU, PMC, Washington, DC, USA, AMEE, Dundee, Scotland, AHA, Houston, TX, USA, and ISPM, Tokyo, Japan
  • Daniel Scherman Centre de Recherche Pharmaceutique de Paris (CRP2); Faculté de Pharmacie, Université Paris Descarte, Centre National de la Recherche Scientifique, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS) Inserm, Paris, France
  • Aleksey Glinushkin N.D. Zelinskii Institute for Organic Chemistry, Russian Academy of Sciences, Moscow, Russia
  • Alan Wu San Francisco General Hospital, and UCSF, San Francisco, CA, USA
  • Tatiana Grishina Dept for Clinical Allergology & Immunology of the Russian University of Medicine, Moscow, Russia
  • Shawn Murphy MGH and Harvard Medical School, Boston, MA, USA
  • Vladimir Zemskov National Medical Research Center for Surgery named after A.V. Vishnevsky, Ministry of Health of the Russian Federation, Moscow, Russia
  • Veronika Polyakova University of World Politics & Law, Moscow, Russia
  • David Smith Mayo Clinic, Rochester, MN, USA
  • Sofya Blokh “Semeinaya-Family” Clinical Practice Network, Russia and Filatov Moscow Children's City Hospital and Research Center, Moscow, Russia
  • R. Holland Cheng T College of Biological Sciences, UC Davis, CA, USA
  • Philip D. Cotter UCSF, San Francisco, CA, USA and ResearchDx and PacificDx, Irvine, CA, USA
  • Vassiliy Tsytsarev Department of Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA
  • Valentina Demidova National Medical Research Center for Surgery named after A.V. Vishnevsky, Ministry of Health of the Russian Federation, Moscow, Russia
  • Mihail Kovalev Department for Obstetrics & Gynecology, Sechenov University, Moscow, Russia

DOI:

https://doi.org/10.14738/bjhmr.111.16340

Keywords:

Biomarker, Biomarker classification, Clinical trial, Companion diagnostics (CDx), Drug development, Personalized and Precision Medicine, Personalized treatment, Biodesign, Predictive biomarker, Prognostic biomarker

Abstract

Drug development continues to move in the direction of the development of clinical practice as applicable to Personalized and Precision Medicine (PPM), - where ideally the most effective therapy or treatment is determined by the genetic makeup of the patient.

Downloads

Published

2024-02-10

How to Cite

Suchkov, S., Scherman, D., Glinushkin, A., Wu, A., Grishina, T., Murphy, S., Zemskov, V., Polyakova, V., Smith, D., Blokh, S., Cheng, R. H., Cotter, P. D., Tsytsarev, V., Demidova, V., & Kovalev, M. (2024). Towards the Biomarker-Driven Development and their Global Impact in the Evidence-Based Clinical Practice of Personalized and Precision Healthcare Services. British Journal of Healthcare and Medical Research, 11(1), 131–157. https://doi.org/10.14738/bjhmr.111.16340

Issue

Vol. 11 No. 1 (2024): British Journal of Healthcare and Medical Research

Section

Original Articles

License

Copyright (c) 2024 Sergey Suchkov, Daniel Scherman, Aleksey Glinushkin, Alan Wu, Tatiana Grishina, Shawn Murphy, Vladimir Zemskov, Veronika Polyakova, David Smith, Sofya Blokh, R. Holland Cheng, Philip D. Cotter, Vassiliy Tsytsarev, Valentina Demidova, Mihail Kovalev

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)